Breast Cancer Research Findings
Home » Guardant360® » Breast Cancer Research Findings

Findings from plasmaMATCH Study

For patients with breast cancer, plasmaMATCH study showed that Guardant360® assay has high sensitivity and detection rate and has sufficient clinical performance for adoption into routine clinical practice1.

Guardant360® testing showed 95% sensitivity overall for targeted sequencing and 100% sensitivity for patients with contemporaneous tissue biopsies1

Contemporaneous Paired Samples (within 60 days)

Guardant360® is able to detect mutations in genes that are clinically important in breast cancer: HER2, ESR1, and PIK3CA1

Mutation Detection Rate, %

Turner NC, Kingston B, Kilburn LS, et. al. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncol. 2020 Oct;21(10):1296-1308. doi: 10.1016/S1470-2045(20)30444-7.

Message us